RxDoctor Payments Data

Amy Tran, DO

Family Medicine · Fairfield, CTNPI 1659862688

Payments from drug & device makers

$354in general payments, 2019–2025

Across 8 payments — averaging $44.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$113
  • AstraZeneca$96
  • Boehringer Ingelheim$50
  • Novo Nordisk$49
  • Aurinia Pharma U.S., Inc.$18
  • Lundbeck LLC$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$354100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$354 in reported general payments places this provider in the 55th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$73,090
Medicare patients
164
Services billed
732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol36$40,352
OzempicSemaglutide36$39,326
JardianceEmpagliflozin28$29,226
JanuviaSitagliptin Phosphate18$26,239
SymbicortBudesonide/Formoterol Fumarate26$7,900
VascepaIcosapent Ethyl13$4,754
Atorvastatin Calcium452$3,270
Rosuvastatin Calcium180$1,921
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,535
Solifenacin Succinate11$1,427
Levothyroxine Sodium126$1,348
SynthroidLevothyroxine Sodium20$1,307
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med22$1,021
Metformin Hcl ErMetformin Hcl63$907
Losartan Potassium95$874

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$96$48,25262 claims
Novo NordiskOzempic$49$39,32636 claims
Boehringer IngelheimJardiance$50$29,22628 claims
MerckJanuvia$14$26,23918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Fairfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →